BIOA
BioAge Labs, Inc.
$20.49
+3.28%
$910.8M
No data for this timeframe.
Vol
Market Cap$910.8M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders50 funds
Inst. Value$268.4M
Inst. Activity15 buys / 4 sells
Insider Activity0B / 2S
Insider Net $-$296.5K
SEC Reports4
Press Releases3
Recent Activity
Jun 16, 2026
Press
BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor)
Impact 3/10
Jun 16, 2026
fda
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral do
Jun 10, 2026
Insider
ENRIGHT PATRICK G was granted 22,000 shares
Director
Jun 10, 2026
Insider
HEALY JAMES was granted 22,000 shares
Director
Jun 10, 2026
Insider
Hemrajani Rekha was granted 22,000 shares
Director
May 8, 2026
SEC
BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $-0.52 vs consensus $
8-K — Impact 7/10
Apr 21, 2026
SEC
BioAge Labs, Inc. is holding its 2026 annual meeting to elect three Class II directors and ratify the appointment of KPM
DEFA14A — Impact 3/10
Apr 1, 2026
SEC
Paul Rubin, an officer of BioAge Labs, filed a Form 144 notifying intent to sell up to 8,820 shares of common stock, exe
144 — Impact 3/10
Price Targets
$49.50
+141.6% upside
Strong Buy
Current $20.49
Low $23.00
Median $51.00
High $73.00
8 analysts
$23.00
$73.00
Analyst Ratings
6Strong Buy
6Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Roth Capital | INITIATE | Buy |
| May 13, 2026 | BTIG | INITIATE | Buy |
| Mar 27, 2026 | Needham | INITIATE | Buy |
| Mar 10, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Feb 25, 2026 | Oppenheimer | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.63 ▲ +1.3% | $-0.75 — $-0.54 | -5% YoY | 6 |
| Next Q | $-0.66 | $-0.85 — $-0.53 | -17% YoY | 6 |
| Current FY | $-2.49 | $-3.03 — $-2.12 | -11% YoY | 7 |
| Next FY | $-2.06 ▲ +25.8% | $-3.02 — $1.15 | 17% YoY | 7 |
Latest Reports
NEUTRAL
Press
3/10
BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor)
Jun 16, 2026
BULLISH
8-K
7/10
BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $-0.52 vs consensus $
May 8, 2026
NEUTRAL
DEFA14A
3/10
BioAge Labs, Inc. is holding its 2026 annual meeting to elect three Class II directors and ratify the appointment of KPM
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $39.7M | ADD |
| JANUS HENDERSON GROUP PLC | $36.6M | DOUBLED |
| RA CAPITAL MANAGEMENT, L.P. | $28.9M | NEW |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.7M | — |
| BALYASNY ASSET MANAGEMENT L.P. | $23.2M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | ENRIGHT PATRICK | A | $0.00 |
| Jun 10, 2026 | HEALY JAMES | A | $0.00 |
| Jun 10, 2026 | Hemrajani Rekha | A | $0.00 |
| Jun 10, 2026 | GARNIER JEAN | A | $0.00 |
| Jun 10, 2026 | Davidson Michael | A | $0.00 |
50 institutional holders with $268.4M total value (15,354,940 shares) as of 2026-Q1. Top holders: BlackRock,, JANUS, RA. Net buying activity: 15 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2,267,756 | $39.7M | 14.8% | ADD +48.5% |
| 2 | JANUS HENDERSON GROUP PLC | 2,094,270 | $36.6M | 13.6% | DOUBLED +411.8% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 1,650,648 | $28.9M | 10.8% | NEW |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1,354,906 | $23.7M | 8.8% | — |
| 5 | BALYASNY ASSET MANAGEMENT L.P. | 1,327,545 | $23.2M | 8.7% | NEW |
| 6 | Polar Capital Holdings Plc | 1,132,640 | $19.8M | 7.4% | NEW |
| 7 | STATE STREET CORP | 850,894 | $14.9M | 5.5% | DOUBLED +101.2% |
| 8 | D. E. Shaw & Co., Inc. | 699,190 | $12.2M | 4.6% | DOUBLED +226.0% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 500,000 | $8.7M | 3.3% | TRIM -52.4% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 286,946 | $5.0M | 1.9% | — |
| 11 | FRANKLIN RESOURCES INC | 265,373 | $4.6M | 1.7% | — |
| 12 | MORGAN STANLEY | 259,869 | $4.5M | 1.7% | ADD +36.6% |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 247,276 | $4.3M | 1.6% | ADD +59.1% |
| 14 | DIMENSIONAL FUND ADVISORS LP | 214,546 | $3.7M | 1.4% | — |
| 15 | VANGUARD FIDUCIARY TRUST CO | 195,937 | $3.4M | 1.3% | — |
| 16 | MARSHALL WACE, LLP | 190,472 | $3.3M | 1.2% | ADD +28.0% |
| 17 | FMR LLC | 190,298 | $3.3M | 1.2% | ADD +61.7% |
| 18 | Invesco Ltd. | 176,110 | $3.1M | 1.1% | — |
| 19 | GOLDMAN SACHS GROUP INC | 156,438 | $2.7M | 1.0% | — |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 138,588 | $2.4M | 0.9% | DOUBLED +653.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 1,527,541 | 2,267,756 | +48.5% | $39.7M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | DOUBLED | 409,207 | 2,094,270 | +411.8% | $36.6M | 2026-Q1 |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 1,650,648 | — | $28.9M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 1,327,545 | — | $23.2M | 2026-Q1 |
| Polar Capital Holdings Plc | NEW | — | 1,132,640 | — | $19.8M | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 422,846 | 850,894 | +101.2% | $14.9M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 1,050,000 | 500,000 | -52.4% | $8.7M | 2026-Q1 |
| FMR LLC | ADD | 117,703 | 190,298 | +61.7% | $3.3M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 18,400 | 138,588 | +653.2% | $2.4M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 41,308 | 63,256 | +53.1% | $1.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 188,683 | 61,508 | -67.4% | $1.1M | 2026-Q1 |
| Trexquant Investment LP | ADD | 39,334 | 60,572 | +54.0% | $1.1M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 82,963 | 59,133 | -28.7% | $1.0M | 2026-Q1 |
| Nuveen, LLC | ADD | 30,794 | 48,688 | +58.1% | $851.6K | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 15,796 | 23,096 | +46.2% | $403.9K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 11,009 | 14,155 | +28.6% | $247.6K | 2026-Q1 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 1,742 | 2,265 | +30.0% | $39.6K | 2026-Q1 |
| NATIONAL BANK OF CANADA /FI/ | TRIM | 45 | 24 | -46.7% | $418.00 | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 14,808 | 21,418 | +44.6% | $375.00 | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 1,050,000 | — | $13.9M | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 198,111 | 422,846 | +113.4% | $5.6M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | DOUBLED | 104,281 | 339,909 | +226.0% | $4.5M | 2025-Q4 |
| MORGAN STANLEY | ADD | 228,158 | 311,659 | +36.6% | $4.1M | 2025-Q4 |
| MARSHALL WACE, LLP | ADD | 174,196 | 222,948 | +28.0% | $2.9M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 11,119 | 188,683 | +1596.9% | $2.5M | 2025-Q4 |
7 unique insiders with 13 transactions. Net insider value: -$296.5K ($0.00 bought, $296.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | ENRIGHT PATRICK G | Director | AWARD | 22,000 | — | — |
| Jun 10, 2026 | HEALY JAMES | Director | AWARD | 22,000 | — | — |
| Jun 10, 2026 | Hemrajani Rekha | Director | AWARD | 22,000 | — | — |
| Jun 10, 2026 | GARNIER JEAN PIERRE | Director | AWARD | 22,000 | — | — |
| Jun 10, 2026 | Davidson Michael H. | Director | AWARD | 22,000 | — | — |
| Apr 23, 2026 | GOLDSTEIN DOV A MD | Chief Financial Officer | EXERCISE | 3,542 | $4.38 | $15.5K |
| Apr 1, 2026 | RUBIN PAUL D | Chief Medical Officer | SELL | 8,820 | $17.81 | $157.1K |
| Apr 1, 2026 | RUBIN PAUL D | Chief Medical Officer | EXERCISE | 5,437 | $4.11 | $22.3K |
| Mar 2, 2026 | RUBIN PAUL D | Chief Medical Officer | EXERCISE | 5,433 | $4.11 | $22.3K |
| Mar 1, 2026 | GOLDSTEIN DOV A MD | Chief Financial Officer | EXERCISE | 3,542 | $4.38 | $15.5K |
| Feb 2, 2026 | RUBIN PAUL D | Chief Medical Officer | EXERCISE | 5,433 | $4.11 | $22.3K |
| Feb 2, 2026 | RUBIN PAUL D | Chief Medical Officer | SELL | 7,433 | $18.75 | $139.4K |
| Feb 1, 2026 | GOLDSTEIN DOV A MD | Chief Financial Officer | EXERCISE | 3,541 | $4.38 | $15.5K |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.8/10.
BULLISH
8-K
7/10
BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $
May 8, 2026
NEUTRAL
DEFA14A
3/10
BioAge Labs, Inc. is holding its 2026 annual meeting to elect three Class II directors and ratify th
Apr 21, 2026
NEUTRAL
144
3/10
Paul Rubin, an officer of BioAge Labs, filed a Form 144 notifying intent to sell up to 8,820 shares
Apr 1, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and Schwab — significantly increased
Feb 28, 2026
NEUTRAL
3/10
BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-1
Jun 16, 2026
BULLISH
8/10
BioAge Labs announced positive Phase 1 results for BGE-102, its oral NLRP3 inhibitor, showing profou
Apr 21, 2026
MIXED
6/10
BioAge Labs reported its full-year 2025 financial results alongside key clinical and corporate updat
Mar 24, 2026
Current analyst consensus: Strong Buy (80% buy). Based on 15 analysts: 6 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$49.50 mean target
+141.6% upside
Strong Buy (1.67)
$23.00 Low
$73.00 High
| Metric | Value |
|---|---|
| Current Price | $20.49 |
| Target Low | $23.00 |
| Target Mean | $49.50 |
| Target Median | $51.00 |
| Target High | $73.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.63 | $-0.75 | $-0.54 | -5.3% | +1.3% | 3↑ 1↓ | $0.0B | -32.7% | 6 |
| Next Q 2026-09-30 |
$-0.66 | $-0.85 | $-0.53 | -17.2% | — | 2↑ 2↓ | $0.0B | -23.2% | 6 |
| Current FY 2026-12-31 |
$-2.49 | $-3.03 | $-2.12 | -11.3% | — | 3↑ 1↓ | $0.1B | 503.1% | 7 |
| Next FY 2027-12-31 |
$-2.06 | $-3.02 | $1.15 | 17.3% | +25.8% | 3↑ 1↓ | $0.0B | -34.8% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.632 | |
| 7d ago | $-0.636 | +0.004 |
| 30d ago | $-0.640 | +0.008 |
| 60d ago | $-0.640 | +0.008 |
| 90d ago | $-0.674 | +0.042 |
7 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 5 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Roth Capital | INITIATE | — | Buy |
| May 13, 2026 | BTIG | INITIATE | — | Buy |
| Mar 27, 2026 | Needham | INITIATE | — | Buy |
| Mar 10, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Feb 18, 2026 | Jefferies | UPGRADE | Hold | Buy |
| Jan 27, 2026 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 6 | 3 | 0 | 0 | 80% | |
| May 1, 2026 | 5 | 5 | 3 | 0 | 0 | 77% | |
| Apr 1, 2026 | 5 | 5 | 3 | 0 | 0 | 77% | |
| Mar 1, 2026 | 5 | 4 | 3 | 0 | 0 | 75% | |
| Feb 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Jan 1, 2026 | 3 | 3 | 4 | 0 | 0 | 60% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 16, 2026
fda
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated syste
May 22, 2026
other
BioAge Labs to Present at Upcoming Investor Conferences
<p align="justify">EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage
May 12, 2026
earnings_calendar
BIOA Q1 2026 Earnings Scheduled — 2026-05-12
May 8, 2026
earnings
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
<p align="justify"><em>Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in infl
May 4, 2026
fda
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
<p align="justify"><em>Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET</em></p>
May 4, 2026
earnings_calendar
BIOA Q1 2026 Earnings Scheduled — 2026-05-04
Apr 21, 2026
fda
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
<p align="justify"><em>120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and e
Apr 13, 2026
other
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
<p align="justify">EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-sta
Mar 24, 2026
earnings
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
<p align="justify"><em>Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3
Mar 19, 2026
earnings_calendar
BIOA Q4 2025 Earnings Scheduled — 2026-03-19